META vs NMAX

META exhibits exceptional fundamental health with a Piotroski F-Score of 8/9, indicating strong financial strength across most key metrics. While the current price of $671.34 trades at a significant premium to the Graham Number ($213.08) and the growth-based Intrinsic Value ($541.67), this is justified by a highly attractive Forward P/E of 18.62 and a PEG ratio of 1.10. The company maintains elite profitability margins (82% Gross, 41.3% Operating) and robust revenue growth of 23.8% YoY. Despite bearish insider sentiment and short-term technical weakness, the underlying operational performance and analyst consensus suggest significant upside toward the $855 target.

NMAX exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all health metrics. Despite maintaining a low debt-to-equity ratio and acceptable liquidity, the company is suffering from severe profitability collapse with an ROE of -205.18% and a profit margin of -52.57%. The stock has experienced a catastrophic long-term decline, losing 92.5% of its value over five years. While analyst target prices suggest a significant upside, the deterministic data points to a high-risk profile with no current evidence of a sustainable turnaround.